Anthony Holler, MD
Anthony Holler, MD is Chairman of the Board of Directors for Perimeter Medical Imaging AI, Inc. He currently serves as the CEO and Chairman of the Board of Directors for Sunniva Inc. Previously, Dr. Holler was Chairman of the Board of Directors of CRH Medical from December 2005 to March 2020. Prior to joining CRH, Dr. Holler was one of the founders of ID Biomedical Corporation. He held a number of executive positions with ID Biomedical, including Chief Executive Officer until the company was acquired by GlaxoSmithKline in December 2005 for $1.7 billion. Dr. Holler was also Chairman of Corriente Resources Inc., which sold for approximately $700 million to CRCC-Tongguan Investment Co. in 2010. Before his involvement in public markets, Dr. Holler served as an Emergency Physician at University Hospital at the University of British Columbia. He holds a Bachelor of Science Degree and a Medical Degree from the University of British Columbia.
Frank Prendergast, MD
Dr. Prendergast has held senior positions within Mayo Clinic: Chair, Department of Biochemistry & Molecular Biology; Director for Research, Mayo Clinic Rochester,'89-'92. Member of the Board of Governors for Mayo Clinic in Rochester; Mayo Clinic Board of Trustees,'92-'09; Mayo Clinic's Board of Governors, '99-'06. Mayo Distinguished Investigator, Emeritus Director of the Mayo Clinic Comprehensive Cancer Center and Emeritus Director of Mayo Center for Individualized Medicine.
Frank also served extensively for the National Institutes of Health, Board of Advisors for Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of National Cancer Institute; National Cancer Advisory Board.
He has received the following honors and awards: Rhodes Scholarship; DSc Purdue University and University West Indies, Outstanding Graduate from University West Indies; Outstanding Graduate College of Biological Sciences from University of Minnesota; Musgrave Gold Medal Institute of Jamaica.
Frank holds a medical degree with honors from University of West Indies; Oxford University Rhodes Scholar M.A. degree in physiology. After internal medicine residency at Mayo Clinic, he obtained the Ph.D. degree in biochemistry at University of Minnesota/Mayo Graduate School.
Suzanne Foster is currently serving as President of At-Home Solutions for Cardinal Health, a global integrated health products and services company. Before joining Cardinal, Suzanne served as President of Stanley Healthcare, as Vice President and General Manager of Medtronic Advanced Energy, VP of Global Business Operations at Salient Surgical Technologies and was a practicing attorney, at Holland & Knight LLP. Suzanne earned her MPH from Harvard and JD from Suffolk University Law School. She is also on the Board of Directors for Unitil Corporation (NYSE: UTL).
Mr. Aaron Davidson is CFO and Senior Vice President of Corporate Development of Profound Medical Inc., a medical technology company that is developing real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Before joining Profound, Mr. Davidson served as Co-Head and Managing Director of H.I.G. BioHealth Partners, where he focused on investment opportunities with emerging life sciences companies. Mr. Davidson began his career with Eli Lilly and Company, where he spent a decade in various operating management roles in the United States and Canada, including financial management, business development, strategic planning, market research and general management. While at H.I.G., he led investments in, worked with the management teams of, and represented H.I.G. as a board member of several successful companies, including Alder Biopharmaceuticals (public), Forsight Vision5 (acquired), Gemin X Pharmaceuticals (acquired), HyperBranch Medical Technology (acquired), Intact Vascular, OnTarget Laboratories, Novadaq Technologies (public/acquired), and Salmedix (acquired). Mr. Davidson earned his MBA from Harvard Business School and a bachelor’s degree in finance from McGill University.
Mr. Ian Mortimer has over 20 years of experience in the biotechnology sector. He is currently President and Chief Executive Officer of Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a company developing innovative therapeutics to improve the lives of patients with neurological disorders. Prior to joining Xenon in 2013, Mr. Mortimer spent six years at Tekmira Pharmaceuticals Corporation, now Arbutus Biopharma Corporation (NASDAQ: ABUS), as Executive Vice President and Chief Financial Officer. He led both Xenon’s and Tekmira’s listings on the NASDAQ, in 2014 and 2010 respectively. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer of Inex Pharmaceuticals Corporation. Mr. Mortimer serves on the board of directors of Xenon and is chair of the board of directors for Appili Therapeutics, Inc., a publicly-traded biopharmaceutical company focused on developing treatments for infectious diseases. Mr. Mortimer has an M.B.A. from Queen’s University, a B.Sc. in Microbiology from the University of British Columbia, and is a Chartered Professional Accountant, Certified Management Accountant.
Mr. Cleland is co-founder and principal at Roadmap Capital, and Portfolio Manager of the Roadmap Innovation Funds. Mr. Cleland has a Bachelor of Arts (Honours, 1992/97) from Harvard University and earned his CFA designation in 2001. He was founding portfolio manager at Northern Rivers Capital Management ("Northern Rivers"), where he managed the Northern Rivers Innovation Fund from May of 2001 until Northern Rivers was acquired by BluMont Capital in February of 2010. He co-founded Roadmap Capital Inc. in the summer of 2013. Roadmap and its investors have now invested more than $145M in VC-stage tech companies. Sectors include semiconductors, cybersecurity, material sciences, and medical devices. Mr. Cleland is now a member of the Board of Directors of Ubilite Inc, Perimeter Medical Imaging, MMB and Corsa Security, and is an observer on the Board of Peraso Technologies. Prior to Northern Rivers, Mr. Cleland also held various roles at Midland Walwyn Capital and Interward Capital Corporation.
Mr. Janzen has been involved in the Life Sciences industry for the past 19 years. He currently is the Founder and President of NorthView Ventures, an entity which invests in and provides strategic advisory services to a number of technology companies. Prior to that, he was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300M from investors and completed over $1Billion in licensing deals during his tenure. In 2010 Cardiome's lead product Brinavess was approved and launched in Europe by Merck. Prior to that, Mr. Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr. Janzen is a past winner of Vancouver's Top 40 under 40 award, is the past Chairman of Life Sciences British Columbia, has served as a Director of Biotech Canada and sits as a Director on a number of public and private boards.
Mr. Zine is the Technology Principal at Roadmap Capital. After completing an undergraduate degree in Electrical Engineering and a Masters in RF Engineering, Mr. Zine earned a Ph.D. in Electrical and Computer Engineering from the University of Calgary in 2006 with a focus on nanotechnology and MEMS engineering. He joined CMC Microsystems in 2007 as a Senior Engineer in Micro and Nanotechnology Fabrication. Mr. Zine was involved with projects related to GaN MMIC (Microwave Monolithic Integrated Circuits) process, MEMS and nanotechnology related products. In 2010, Mr. Zine moved to the Business Development Department to work as a Technology Advisor, Microsystems and Nanotechnology, where he worked on projects in Photonics, printed electronics and packaging.